Steris에 대한 매도 수량은 투자자에게 Steris의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Steris (NYSE:STE) 주식, 공매도 수량 보고

Steris

Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.

Upgrades

Markets

Analyst Ratings

Trading Ideas

TSLA

월스트리트의 주요 애널리스트들이 이들 주요 기업들에 대한 전망을 변경했다. 애널리스트의 모든 등급 변경 사항을 완전하게 보려면, 애널리스트 등급 페이지를 참조하세요.

테슬라 분석가가 긍정적으로 전환; 목요일 업그레이드 상위 5종목

News

Movers

EQIX

TEVA

TOST

이들 대형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?테바 파마슈티컬 인더스트리즈(NYSE:TEVA)의 주가는 회사가 엇갈린 1분기 재무 결과를 발표하고 위약과 비교하여 정신분열증이 있는 성인 환자를 대상으로 한 TEV-&#39;749의 3상 솔라리스(SOLARIS) 시험의 효능 부분 결과를 발표했한 후 16.24% 급등했다. 

지난주(5월 5일~5월 11일) 최고의 성과를 낸 10개의 대형주

Steris PLC

Stream Media Corp

Santech Holdings Limited - American Depositary Shares

Santech Holdings Ltd

Scatec ASA

STEER Technologies Inc Ordinary Shares

Steem

STATE ENERGY GRP by STATE ENERGY GROUP INTL ASSETS HLDGS LTD.

Majestic Dragon AeroTech Holdings Ltd

Sintana Energy Inc Warrants (08/03/2024)

Stemtech Corp

Stellar Bancorp Inc

Stem Inc

StepStone Group Inc. - Class A Common Stock

StepStone Group Inc

Step Finance - United States Dollar

STERLING CHECK CORP COM

Lido stETH

Stevia Corp

SRH Total Return Fund, Inc.

Needham analyst Mike Matson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Steris

WIIM

Steris shares are trading lower after the company reported worse-than-expected Q2 revenue results

Stephens &amp; Co. analyst Jacob Johnson reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and maintains $260 price target.

Price Target

Stephens & Co. Reiterates Overweight on Steris, Maintains $260 Price Target

Guidance

Steris Reiterates FY25 As Reported Revenue To Increase 6.5-7.5%, Adj EPS From Continuing Operations To Be $9.05 - $9.25, Est $9.16

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent. The company reported quarterly sales of $1.33 billion which met the analyst consensus estimate. This is a 1.04 percent decrease over sales of $1.34 billion the same period last year.

Earnings

Earnings Beats

Steris Q2 2025 Sales $1.328B, Miss $1.33B Estimate

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent.

Steris Q2 2025 Adj EPS $2.14 Beats $2.12 Estimate

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Steris to report an earnings per share (EPS) of $2.12.
Steris bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.05, leading to a 2.36% drop in the share price the following trading session.
Here's a look at Steris's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.98</td>
<td>2.38</td>
<td>2.17</td>
<td>2.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.03</td>
<td>2.58</td>
<td>2.22</td>
<td>2.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>8.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730836886_0.png" alt="eps graph" />
<h3>Performance of Steris Shares</h3>
Shares of Steris were trading at $225.82 as of November 04. Over the last 52-week period, shares are up 10.14%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/STE/earnings">To track all earnings releases for Steris visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Steris

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>KGI Securities analyst Terry Lee upgraded Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) from Neutral to Outperform and announced a $276 price target. Tesla shares closed at $213.65 on Wednesday. <a href="https://www.benzinga.com/quote/tsla/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Matt O&#8217;Connor upgraded the rating for Regions Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) from Hold to Buy and increased the price target from $24 to $26. Regions Finl shares closed at $23.64 on Wednesday. <a href="https://www.benzinga.com/quote/RF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587781de5064ed0001730076/mark-strouse">JP Morgan analyst Mark Strouse</a> upgraded NextEra Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEP#NYSE">NEP</a>) from Underweight to Neutral but lowered the price target from $25 to $22. NextEra Energy Partners shares closed at $21.01 on Wednesday. <a href="https://www.benzinga.com/quote/NEP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e8b4df71e7bd60001d9d077/jason-bednar">Piper Sandler analyst Jason Bednar</a> upgraded STERIS plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) from Neutral to Overweight and boosted the price target from $230 to $260. Steris shares closed at $221.15 on Wednesday. <a href="https://www.benzinga.com/quote/STE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna analyst Bascome Majors upgraded the rating for Canadian Pacific Kansas City Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) from Neutral to Positive but slashed the price target from $94 to $92. Canadian Pacific Kansas shares closed at $78.83 on Wednesday. <a href="https://www.benzinga.com/quote/CP/analyst-ratings">See how other analysts view this stock.</a> </li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-1024x530.png" alt="" class="wp-image-612833" style="width:555px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/24140730/image-243.png 1228w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41517173/eaton-transdigm-and-a-big-bank-on-cnbcs-final-trades">Eaton, TransDigm And A Big Bank On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>

This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

STERIS shares are trading higher after Piper Sandler upgraded the stock from Neutral to Overweight and raised its price target from $230 to $260.

4 analysts have expressed a variety of opinions on Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $262.5, with a high estimate of $265.00 and a low estimate of $260.00. This upward trend is apparent, with the current average reflecting a 3.96% increase from the previous average price target of $252.50.
<img src="https://www.benzinga.com/files/images/story/2024/1729778431_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Steris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Steris. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Steris's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Steris's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Breaking Down Steris's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Steris's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.12%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Steris's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Steris's ROA excels beyond industry benchmarks, reaching 1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Steris

Piper Sandler analyst Jason Bednar upgrades Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) from Neutral to Overweight and raises the price target from $230 to $260.

Piper Sandler Upgrades Steris to Overweight, Raises Price Target to $260

Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading higher on Tuesday.</a>
Constellation Brands has revised its FY25 comparable EPS forecast to $13.60 &#8211; $13.80, compared to the previous forecast of $13.50 &#8211; $13.80. This is compared to <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">the $13.70 estimate.</a>
Constellation Brands projects FY25 reported EPS in the range of $3.05 &#8211; $7.92, down from the previous forecast of $14.63 &#8211; $14.93 and well below the $14.62 estimate.
The company anticipates a hefty non-cash goodwill impairment loss of around $1.5 billion to $2.5 billion for its Wine and Spirits division in the second quarter of fiscal 2025, which is factored into the revised reported&nbsp;EPS outlook.
The company also revised its Enterprise net sales growth forecast to 4% &#8211; 6% (from 6% &#8211; 7% prior), citing incremental macroeconomic headwinds affecting consumers, particularly unemployment and prolonged inventory destocking in wine and spirits markets.
The company updated Beer net sales growth to 6% &#8211; 8%&nbsp;(from 7% &#8211; 9% prior) and Wine and Spirits net sales outlook to (6)% &#8211; (4)% (from (0.5)% &#8211; 0.5% prior).
&#8220;While ongoing macroeconomic headwinds, particularly rising unemployment, have led to a recent deceleration in the rate of growth of consumer demand for our products, we are on track to deliver a solid mid single-digit volume increase this fiscal year for our Beer Business,&#8221; said Constellation Brands President and Chief Executive Officer Bill&nbsp;Newlands.
&#8220;These trends have been most notable in the top five states for our Beer Business, which account for just over half of our volumes; however, we continue to see volume growth within the low to mid single-digit range in these states and within the high single-digit range on average across the rest of the country.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/23/05/32347463/steris-delivered-strong-q4-performance-but-analyst-call-fy24-outlook-mixed" rel="noreferrer noopener">Steris Delivered Strong Q4 Performance, But Analyst Call FY24 Outlook Mixed</a>
The CEO noted that improvements from earlier initiatives benefit major brands in the Wine and Spirits sector, although category challenges continue to impact the fiscal year outlook.
Despite these challenges, the company has outpaced the CPG sector growth by nearly 3 percentage points in dollar sales and its Beer Business has achieved notable gains, including being the top dollar share gainer in its category and the third largest in the Beverage industry.
RBC Capital analyst Nik Modi reaffirms Constellation Brands with an Outperform rating and maintains a $308 price target.
Price Action: STZ shares are sharing higher by 3.08% to $248.12 at last check Tuesday.
Photo: Engin Akyurt from Pixabay.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40669363/teslas-china-rivals-report-steady-august-sales-performance-amid-intense-price-competition-what-i" target="_blank" rel="noreferrer noopener">Tesla's China Rivals Report Steady August Sales Performance Amid Intense Price Competition: What Investors Should Know</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

General

What's Going On With Constellation Brands Stock Today?

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $263.75, along with a high estimate of $265.00 and a low estimate of $260.00. This upward trend is evident, with the current average reflecting a 0.96% increase from the previous average price target of $261.25.
<img src="https://www.benzinga.com/files/images/story/2024/1725379219_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Steris among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$265.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Steris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Steris's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Steris's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>Discovering Steris: A Closer Look</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Steris displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 8.12%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Steris's net margin excels beyond industry benchmarks, reaching 11.36%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Steris's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.3%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Steris's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.37%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Steris's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.39.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Steris Stands With Analysts

Keybanc analyst Brett Fishbin maintains Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Overweight and raises the price target from $255 to $265.

Keybanc Maintains Overweight on Steris, Raises Price Target to $265

A new SEC filing reveals that CHRISTOPHER HOLLAND, Board Member at Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), made a notable insider purchase on August 12,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001757898/000162828024036792//Archives/edgar/data/1757898/000162828024036792/0001628280-24-036792-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that HOLLAND purchased 988 shares of Steris. The total transaction amounted to $236,803. 
Monitoring the market, Steris's shares down by 0.0% at $233.94 during Tuesday's morning.
<h3>Get to Know Steris Better</h3>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Steris's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Steris showcased positive performance, achieving a revenue growth rate of 8.12% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 44.74%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Steris's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 1.46.
</li>
</ul>
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.39, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 41.41 is lower than the industry average, implying a discounted valuation for Steris's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The Price to Sales ratio is 4.44, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 18.19 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001757898">Check Out The Full List Of Steris's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Move: CHRISTOPHER HOLLAND Invests $236K In Steris Stock

In the preceding three months, 4 analysts have released ratings for Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Steris and provided 12-month price targets. The average target is $253.75, accompanied by a high estimate of $265.00 and a low estimate of $225.00. Marking an increase of 0.5%, the current average surpasses the previous average price target of $252.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1723064454_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Steris's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Steris. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Steris compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Steris's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Steris's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Steris analyst ratings.</a>
<h2>About Steris</h2>
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
<h3>Unraveling the Financial Story of Steris</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Steris displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 15.87%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Steris's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -0.12%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Steris's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.02%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Steris's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.01%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Steris's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Steris: Insights From 4 Financial Analysts

JMP Securities analyst David Turkaly reiterates Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) with a Market Outperform and maintains $265 price target.

JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target

STERIS plc&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ste#NYSE">STE</a>) reported first-quarter fiscal 2025 adjusted earnings per share of $2.03, up 10.3% from the year-ago quarter&#39;s figure. The figure surpassed the Zacks Consensus Estimate by 2 cents.
The adjustment excludes the impacts of certain non-recurring charges, such as the amortization of acquired intangible assets and acquisition and integration-related charges, among others.
The company&#39;s GAAP EPS was $1.41, up 7.6% from the year-ago level of $1.31. &nbsp;
<h3>Revenues in Detail</h3>
Revenues of $1.28 billion from continuing operations increased 8.5% year over year. The figure outpaced the Zacks Consensus Estimate by 1.5%.
Organic revenues at the constant exchange rate or CER rose 6% year over year.
<h3>Quarter in Detail</h3>
The company operates through three segments &mdash; Healthcare, Applied Sterilization Technologies (&quot;AST&quot;), and Life Sciences.
Revenues at&nbsp;Healthcare&nbsp;rose 10% year over year to $901.2 million (up 5% on a CER organic basis). While there was a 23% improvement in consumable revenues and a 14% increase in service revenues, these were partially offset by a 10% decline in capital equipment revenues.&nbsp; Our model expected Healthcare segment revenues to improve 6.9% in the fiscal first quarter.
Revenues at&nbsp;AST&nbsp;improved 7% to $249.8 million (up 8% on a CER organic basis). This performance reflected 7% growth in service revenues and a 24% increase in capital equipment revenues. Our model anticipated a 6.4% improvement in the segment&#39;s revenues in the reported quarter.
Revenues in the&nbsp;Life Sciences&nbsp;segment decreased 2% to $128.5 million (up 4% year over year on a CER organic basis). The decline in revenues was due to the divestiture of the CECS business. This performance reflected 13% growth in consumable revenues, offset by a 15% decline in capital equipment revenues and a 17% decline in service revenues. Our model projected a year-over-year improvement of 5.8% in the segment&#39;s revenues.
<h3>Margins</h3>
The gross profit in the reported quarter was $572.4 million, up 8.2% from the prior-year quarter. The gross margin expanded a marginal 4 basis points (bps) year over year to 44.7% due to an 8% rise in the cost of revenues.
STERIS witnessed a 9.5% year-over-year rise in selling, general and administrative expenses. The figure amounted to $335.6 million. Research and development expenses rose 3.6% to $25.6 million. Adjusted operating expenses of $361.2 million increased 9% year over year. The adjusted operating margin contracted 20 bps to 16.5%.
<h3>Financial Details</h3>
STERIS exited the first quarter of fiscal 2025 with cash and cash equivalents of $198.3 million compared with $207 million at the end of fiscal 2024.
<div class="chart_embed">
<h3>STERIS plc Price, Consensus and EPS Surprise</h3>
<img alt="STERIS plc Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/1e/1723034957.png" style="height:265px; width:590px" title="" />
STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote
</div>
Cumulative net cash flow from operating activities at the end of the fiscal first quarter was $303.7 million compared with $123.8 million in the year-ago period. Further, the company has a&nbsp;five-year&nbsp;annualized dividend growth rate of 8.44%.
<h3>Guidance</h3>
STERIS reiterated its fiscal 2025 projection.
The company expects revenues to increase 6.5-7.5%. Organic revenues are expected to be 5-7% at CER.
The Zacks Consensus Estimate for fiscal 2025 revenues is pegged at $5.48 billion, implying 7.3% growth from fiscal 2024.
Adjusted EPS is expected to be in the range of $9.05-$9.25. The Zacks Consensus Estimate for the metric is pegged at $9.16.
<h3>Our Take</h3>
STERIS exited the first quarter of fiscal 2025 with better-than-expected results, wherein both adjusted earnings and revenues beat their respective consensus estimate. The ongoing momentum of the Healthcare segment is attributed to a solid procedure volume growth in the United States, along with favorable pricing.
The addition of the surgical instrumentation assets purchased from BD was a positive factor behind the strong growth of Healthcare operating income. Further, the AST segment reflected an improvement in capital equipment revenues and service revenues in the quarter under review. The expansion of the gross margin bodes well for the stock.
Meanwhile, performance in Life Sciences was dented due to the divestiture of the CECS business. The contraction of the operating margin is concerning.
<h3>Zacks Rank &amp; Key Picks</h3>
STERIS currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical, Abbott Laboratories, Inc.&nbsp;and Quest Diagnostics.
Intuitive Surgical reported a second-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgical has a long-term earnings growth rate of 16.1% for 2024 compared with the industry&#39;s 14.1%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.97%.
Abbott, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2024 earnings of $1.14 per share, which surpassed the Zacks Consensus Estimate by 3.6%. Revenues of $10.38 billion topped the Zacks Consensus Estimate by 0.3%.
ABT has an earnings growth rate of 10.1% for 2025 compared with the S&amp;P 500&#39;s 9.3%. The company beat on earnings in each of the trailing four quarters, the average surprise being 2.34%.
Quest Diagnostics, carrying a Zacks Rank #2 at present, reported a second-quarter adjusted EPS of $2.35, which surpassed the Zacks Consensus Estimate by 1.7%. Revenues of $2.40 billion outpaced the Zacks Consensus Estimate by 0.5%.
DGX has a historical five-year earnings growth rate of 7.4% compared with the industry&#39;s 4.2%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.
<a href="https://www.zacks.com/stock/news/2318207/steris-ste-q1-earnings-beat-estimates-operating-margin-falls?cid=CS-BENZ-FT-analyst_blog|earnings_article-2318207">To read this article on Zacks.com click here.</a>

Biotech

Large Cap

STERIS Q1 Earnings Beat Estimates, Operating Margin Falls

Piper Sandler analyst Jason Bednar upgraded the rating on Steris (STE – Research Report) to a Buy today, setting a price target of $260.00. Jason B...

Steris: Attractive Risk/Reward Profile and Strong Growth Potential Justify Buy Rating

Piper Sandler upgraded Steris (STE) to Overweight from Neutral with a price target of $260, up from $230. The upgrade is more a call that the negat...

Steris upgraded to Overweight from Neutral at Piper Sandler

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

Steris raised to overweight by Piper Sandler, valuation cited

JMP Securities analyst David Turkaly has reiterated their bullish stance on STE stock, giving a Buy rating yesterday. David Turkaly's rating is bas...

Steris's Strong Financial Performance and Strategic Focus Drive Positive Analyst Rating

Steris Non-GAAP EPS of $2.14 beats by $0.01, revenue of $1.3B

In a report released today, David Turkaly from JMP Securities reiterated a Buy rating on Steris (STE – Research Report), with a price target of $26...

Strong Financial Performance and Growth Potential Drive Buy Rating for Steris

Needham analyst Michael Matson maintained a Hold rating on Steris (STE – Research Report) today. The company's shares opened today at $225.05. Mats...

Steris (STE) Receives a Hold from Needham

STERIS plc (STE) Q2 2025 Earnings Call Transcript

Assessing MedTech impact from potential China tariffs

CATX

CGEM

CGON

GEHC

HAFC

IDYA

IOVA

JANX

KURA

MASI

MRUS

NRIX

NUVL

NVST

SIRI

SNDX

SOLV

TNDM

Dividends

Press Releases

STERIS Announces Dividend of $0.52 per share

STERIS Announces Financial Results for Fiscal 2024 Fourth Quarter and Full Year

PEAK ROCK CAPITAL AFFILIATE COMPLETES PREVIOUSLY ANNOUNCED ACQUISITION OF HUFRIEDYGROUP

STERIS to Host a Conference Call for Fiscal 2025 First Quarter Financial Results on August 7, 2024

STERIS Raises Dividend to $0.57 per share

STERIS Announces Financial Results for Fiscal 2025 First Quarter

STERIS to Present at the Morgan Stanley Healthcare Conference

STERIS to Host a Conference Call for Fiscal 2025 Second Quarter Financial Results on November 7, 2024

STERIS Declares Dividend of $0.57 per share

STERIS Announces Financial Results for Fiscal 2025 Second Quarter

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

ResMed

Smith & Nephew

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Comments

Steris

매도 수량

Steris (NYSE:STE) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌